Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinal bipolar cell multi-characteristic opsin (MCO‑010) is a synthetic light-sensitive protein designed for optogenetic restoration of vision in patients with advanced inherited retinal degenerations such as retinitis pigmentosa. MCO‑010 is engineered from three non-mammalian proteins to create a broadband opsin that responds to ambient visible light. It is delivered using an adeno-associated virus serotype 2 (AAV2) vector under the control of an ON-bipolar cell-specific promoter, ensuring targeted expression in surviving second-order neurons after photoreceptor loss[4][3]. This approach enables these inner retinal neurons—normally not directly photosensitive—to respond to light and transmit visual information downstream. Clinical studies have shown that intravitreal injection of AAV2-MCO‑010 can restore measurable visual function—including improved acuity and mobility—in legally blind patients with severe photoreceptor degeneration. The treatment has demonstrated good tolerability without serious adverse events; mild inflammatory responses have been managed successfully with steroids[6]. Preclinical models also show preservation of remaining retina structure and function following treatment[3]. This target is not a naturally occurring receptor or enzyme but rather represents the therapeutic introduction of a synthetic photosensitive molecule into human ON-bipolar cells for disease modification and functional restoration. Therefore, while it functions as a therapeutic target within the context of gene therapy for blindness, it does not fit traditional molecular classification schemes used for endogenous drug targets. Note on correctness: The original query refers broadly to "Retinal bipolar cell light sensitivity restoration via synthetic multi-characteristic opsin expression," which describes an approach rather than a single canonical molecule/receptor name. The most accurate canonical form based on current literature would be "Retinal bipolar cell multi-characteristic opsin (MCO‑010)" or simply "Multi-characteristic opsin" when referring specifically to this therapeutic entity[4][2].
Photosensitization of ON-bipolar cells via expression of a synthetic, broad-spectrum light-sensitive cation channel protein delivered by AAV2 vector[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal bipolar cell multi-characteristic opsin (MCO-010) (MCO-010).